flow trial semaglutide nejm 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants The FLOW trial: #semaglutide significantly

leveraging genomics and AI by integrating transcriptomics with clinical and laboratory data to generate personalized recommendations ( e.g

Horton JD, Shimano H, Hamilton RL, Brown MS, Goldstein JL (1999) Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL

NG239 Vitamin B12 deficiency in over 16s: diagnosis and management risk factors and symptoms

The decision to use both medications simultaneously should be individualized based on the patient's overall metabolic profile, cardiovascular risk, and treatment goals

When Zepbound (Tirzepatide) is taken with insulin and the insulin dose is reduced too quickly, it can lead to high blood sugar (hyperglycemia), which increases the risk of diabetic ketoacidosis

Which is the No